U.S. markets close in 4 hours 55 minutes
  • S&P 500

    3,294.49
    +23.46 (+0.72%)
     
  • Dow 30

    26,579.25
    +59.30 (+0.22%)
     
  • Nasdaq

    11,126.31
    +121.44 (+1.10%)
     
  • Russell 2000

    1,552.67
    +9.40 (+0.61%)
     
  • Crude Oil

    36.04
    -1.35 (-3.61%)
     
  • Gold

    1,871.70
    -7.50 (-0.40%)
     
  • Silver

    23.44
    +0.08 (+0.35%)
     
  • EUR/USD

    1.1680
    -0.0070 (-0.60%)
     
  • 10-Yr Bond

    0.8150
    +0.0340 (+4.35%)
     
  • GBP/USD

    1.2920
    -0.0068 (-0.52%)
     
  • USD/JPY

    104.4960
    +0.1950 (+0.19%)
     
  • BTC-USD

    13,413.58
    +250.19 (+1.90%)
     
  • CMC Crypto 200

    264.45
    +21.77 (+8.97%)
     
  • FTSE 100

    5,600.31
    +17.51 (+0.31%)
     
  • Nikkei 225

    23,331.94
    -86.57 (-0.37%)
     

Biotech Stock Exploding Higher After Good News On Liver Disease Drugs

Myles Udland
laboratory
laboratory

REUTERS/Mike Brown

Shares of Intercept Pharmaceuticals were up 50% in pre-market trade on Tuesday after the company announced development updates for several of its drug candidates.

The company, which has a market cap of more than $5 billion, also reported second quarter earnings, posting a larger than expected quarterly loss.

Intercept is a biopharmaceutical company focused on the development of liver disease treatments.

Intercept shares, which were halted ahead of the company's announcement on Monday afternoon, were up nearly 250% year-to-date as of Monday's close, with the stock nearly quadrupling in one day on January 9 after the company stopped its FLINT trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis, or NASH, due to "early efficacy."

In its 10-Q filed with the SEC on Monday afternoon, Intercept outlined new developments for its FLINT trial.

On Monday, the company also gave the following updates on its development programs:

  • NASH Program

    • FLINT trial data provided in 10-Q filing and to be discussed on today's conference call

    • Phase 3 program initiation anticipated in 1H 2015, pending regulatory feedback

    • Phase 2 lipid metabolism trial initiation anticipated in 1H 2015

  • PBC Program

    • Fast Track designation granted by FDA

    • Phase 3 confirmatory trial protocol finalization anticipated in 3Q 2014 and initiation planned around year-end 2014

    • Pre-NDA and pre-MAA meetings anticipated in 4Q 2014 with completed filings anticipated in 1H 2015

  • Primary Sclerosing Cholangitis (PSC) Program

    • Double-blind phase 2 trial initiation anticipated year-end 2014

    • First clinical trial of OCA in this orphan indication with high unmet medical need

  • INT-767 Phase 1 Trial Initiation Anticipated in 1H 2015

TheStreet.com's biotech reporter Adam Feuerstein broke down the results last night, writing that the rally in shares, "reflects a sence of relief that OCA head into a registration-worthy phase III study next year with less risk."



More From Business Insider